Shares of Elicio Therapeutics Inc. (ELTX) touched a new high of $12.42 in early trading today, as investors await a major clinical trial milestone in the coming months, particularly in the fourth quarter.
Elicio is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. Its lead investigational asset is ELI-002, a lymph node-targeted mutant Kristen rat sarcoma (mKRAS) cancer vaccine.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.